|
|
Other links at Articles > Diabetes and Endocrinology |
| 1. |
Long-term Effects of Pegvisomant in Patients With Acromegaly
|
|
|
Some patients with acromegaly cannot attain biochemical remission despite various therapeutic approaches. Pegvisomant suppresses insulin-like growth factor 1 production. The efficacy and related risks and benefits of this therapy for acromegaly are described. Nature Clinical Practice Endocrinology & Metabolism
|
|
|